M.D. Anderson Cancer Center
To look at the safety and effectiveness of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.
Primary Objectives: \- To evaluate the efficacy of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART. Secondary Objectives: \- To evaluate safety and tolerability of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART. Exploratory Objective: \- To investigate biomarkers of response and resistance to emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.
Inclusion Criteria: Eligible participants will be considered for inclusion in this study if they meet the following criteria based on tests obtained less than 4 weeks from first dose: 1. Relapsed or refractory FL (grade 1, 2, 3a and 3b), MCL, DLBCL, PMBCL, tFL, or HGBCL 2. Received standard of care therapy with axi-cel, tisa-cel or liso-cel 3. Age ≥ 18 years 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 5. Either in remission after CART and/or with refractory/progressive disease not requiring urgent treatment in the opinion of the treating physician 6. Grade 3-…
Given by Infusion
Arctuva estimate
Verify or correct the compensation shown for this listing.